Assessment of high density lipoprotein in coronary artery disease
Research type
Research Study
Full title
Assessment of high density lipoprotein (HDL) function in coronary artery disease in a nested case-control study
IRAS ID
218504
Contact name
Usha Menon
Contact email
Sponsor organisation
Joint Research Office (JRO)
Clinicaltrials.gov Identifier
Z6364106/2016/11/107, UCL Data Protection Registration
Duration of Study in the UK
2 years, 0 months, 0 days
Research summary
The reduction of cardiovascular disease has been a tremendous success for healthcare worldwide. With access to effective drugs like statins, improved interventions and widespread encouragements for improvements in lifestyle the death rate attributable to cardiovascular diseases has decreased by 35% from 2000 to 2013. However, despite these trends cardiovascular disease remains the leading cause of premature death worldwide and a substantial public health concern.
An unmet need in the diagnosis of cardiovascular disease is effective prognostic testing. A series of high profile publications have supported inverse relationship between high density lipoprotein (HDL) function and coronary artery disease (CAD), potentially bringing new diagnostic insight. Cleveland HeartLab has developed a robust and high-throughput multiplex proteomic measurement of measuring HDL function. Internal research has demonstrated good correlation to the traditional measurements of function retaining the inverse relationship to cardiovascular disease previously described in the literature. Thus this technology has characteristics that could make it suitable for deployment in a clinical laboratory.
The aim of this project is to validate the use of a novel HDL proteome estimator of cholesterol efflux for the determination of cardiovascular risk. For this, longitudinal pre-diagnosis serum samples collected from volunteers during the course of the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) trial who were diagnosed with a myocardial infarction as well as serum samples collected at one single time point will be used. Controls (no record of a myocardial infarction event) will also be selected for comparison. Analysis of the HDL profile in these samples over time that might indicate the presence of cardiovascular risk year(s) before clinical diagnosis could have considerable benefit for the patients.
REC name
London - Bromley Research Ethics Committee
REC reference
16/LO/2228
Date of REC Opinion
27 Jan 2017
REC opinion
Further Information Favourable Opinion